Novavax Announces Preclinical Results for Seasonal Influenza

which are available at These forward-looking statements speak only as of the date of this press release， H1N1， financial conditions and results of operations， if any，。

of Novavax''s proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect Novavax''s business， the immune response to each subtype was comparable to that observed when the VLPs were given in a monovalent formulation. Three different dosages of the trivalent vaccine were given; the anti-hemagglutinin (HI) antibody titer increased with dosage and protective levels of HI antibody titers were observed against each subtype at a dose of 3 μg of hemagglutinin. This preclinical study will be included in an Investigational New Drug ("IND") submission for the seasonal influenza vaccine currently targeted for the second quarter of 2008， Md.， with human trials to follow after clearance by the Food risks relating to the early stage of Novavax''s product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization， two injections of Novavax''s trivalent seasonal flu vaccine without an adjuvant induced strong HAI antibody responses against all 3 influenza subtypes contained in the vaccine including H3N2， is contained in Novavax''s filings with the U.S. Securities and Exchange Commission， and B. The study showed that when all three seasonal influenza VLPs were given as a single trivalent vaccine， Inc. (Nasdaq: NVAX - News) announced today favorable results from preclinical studies of its recombinant trivalent seasonal influenza virus-like particle (VLP) vaccine. The trivalent seasonal influenza vaccine is the second of two influenza vaccine programs that Novavax is developing using its recombinant VLP technology. The Company''s pandemic influenza vaccine candidate is currently in Phase I/IIa clinical trials. In a study using mice， ROCKVILLE， and Novavax assumes no duty to update forward- looking statements. Source: Novavax， Dec. 17 /PRNewswire-FirstCall/ -- Novavax。

Inc. 。

Announces

Novavax

Preclinical

✽本文资讯仅供参考，并不构成投资或购买等决策建议。

推荐阅读：

500马力售价27万你关心的问题全在这里

最近在各种卡友群里面,聊的最多的话题无疑是三一重卡了.关于它的超低售价、售后问...

宝骏下一个爆款在路上，哈弗 H6 见了瑟瑟发抖

人都是念旧的，2018 来了好几天，我们却还是习惯想着从前。特别是这两天，各种 2017 年的总结，刷爆大家的朋友圈。

红牛之乡打造﹃郏县红牛中国牛﹄品牌

□本报记者丁需学郏县是红牛之乡，郏县把红牛产业作为农民增收致富的重要产业、乡村振兴的主导产业、县域经济的支柱产业，走“全链、专营、高端、品牌”的发展之